Methods for treating a CB2 receptor-related disorder (e.g., pain, fibrosis) are provided. These methods are directed to reducing the risk of adverse events based on reduced blood pressure and/or heart rate in subjects in need of treatment with a CB2 receptor agonist compound (e.g., APD371).